Tempus AI, Inc., a leading company in the genomics and AI-driven healthcare industry, has released its latest Form 10-Q report, showcasing significant improvements in both financial and operational metrics. The report highlights the company's robust revenue growth, improved operational efficiency, and strategic initiatives aimed at expanding its market presence and technological capabilities.\n\nFinancial Highlights\nTotal Net Revenue: $314.6 million, marking a 90% increase compared to the same period in 2024. This growth is attributed to a higher volume of tests performed in the Genomics segment and increased data deliveries in the Data and Services product line.\nCost of Revenues: $119.6 million, up by 32% from the same period in 2024, primarily due to increased material and service costs related to the Ambry Acquisition.\nLoss from Operations: $(61.8) million, a significant improvement from a loss of $(533.5) million in the same period in 2024, reflecting a substantial reduction in stock-based compensation expenses.\nNet Loss: $(42.8) million, improved from a net loss of $(552.2) million in the same period in 2024, driven by increased revenue and reduced stock-based compensation expenses.\nAdjusted EBITDA: $(5.6) million, an improvement from $(31.2) million in the same period in 2024, indicating better operational efficiency and cost management.\n\nBusiness Highlights\nTempus AI operates three primary product lines: Genomics, Data, and AI Applications. The Genomics segment, which includes Oncology and Hereditary testing, saw significant growth due to the acquisition of Ambry Genetics. The Data and Services segment also experienced increased revenue, driven by higher demand for Insights products, particularly from existing customers and new agreements like the Pathos Foundation Model.\nSales Units: The volume of Genomics tests increased significantly, with approximately 212,000 tests conducted in the three months ended June 30, 2025, compared to 66,500 in the same period in 2024. This includes 128,000 Hereditary tests following the Ambry acquisition.\nNew Product Launches: The company continues to develop new laboratory assays and algorithms, expanding its Platform into new disease areas. This includes the development of Intelligent Diagnostics using AI to enhance laboratory test accuracy and personalization.\n\nFuture Outlook: Tempus AI plans to maintain high levels of investment in product innovation, technology, and customer acquisition. The company aims to expand its Platform's capabilities and increase adoption of its products across various customer segments, including healthcare providers and pharmaceutical companies.\n\nStrategic Collaborations: The company entered into agreements with AstraZeneca and Pathos to develop a large multimodal model in oncology, leveraging de-identified datasets. This collaboration is expected to enhance the company's data capabilities and product offerings.\n\nOperational Strategy: Tempus AI is focused on rebuilding the data flow ecosystem in healthcare, establishing new data pipes for seamless data exchange between providers and life science companies. This strategy aims to improve data-driven decision-making in clinical settings.\n\nTechnology Investments: Significant investments are being made in the company's technology platform to improve user experience and data structuring efficiency. This includes enhancements to support current and future business needs, particularly in cloud infrastructure and new business lines.\n\nSEC Filing: Tempus AI, Inc. [ TEM ] - 10-Q - Aug. 08, 2025

Tempus AI, Inc. SEC 10-Q Report

Tempus AI, Inc. has published its latest Form 10-Q report, reporting a 90% year-over-year increase in total net revenue to $314.6 million, driven by higher test volumes in the Genomics segment and increased data deliveries in the Data and Services line. The company highlights improved operational efficiency, with a significant reduction in loss from operations from $(533.5) million to $(61.8) million and a net loss decrease from $(552.2) million to $(42.8) million. Key growth drivers include the acquisition of Ambry Genetics, increased sales of 212,000 Genomics tests (up from 66,500), and new product developments such as Intelligent Diagnostics using AI. Strategic collaborations with AstraZeneca and Pathos are underway to co-develop a multimodal oncology model using de-identified datasets. The company is also investing in technology and data infrastructure to enhance data flow between healthcare providers and life science companies.